Medivir: R&D Day

Today, 12:30 GMT, 13:30 CET, London

LONDON, November 18, 2010 - Medivir AB (OMX: MVIR), the emerging research-based specialty
pharmaceutical company focused on infectious diseases, will today host an R&D
day for sell-side analysts, investors and the media at the offices of
M:Communications, 1 Ropemaker Street, 34th Floor, London EC2Y. Registration
for the event will commence at 12:30 (GMT)/13:30 (CET)/7.30 (EST).

Medivir's CEO, Ron Long, and CFO, Rein Piir, will chair the event
together with other key members of Medivir's management team including Eva
Arlander, VP Medivir Pharma, Paul Wallace, VP Business Development, and
Bertil Samuelsson, CSO. Together they will discuss the clinical development
of Medivir's key pipeline asset TMC435, a once daily hepatitis C protease
inhibitor in phase 2b development, which is jointly developed by Medivir and
Tibotec Pharmaceuticals, and present an update on the product and R&D
pipeline.

In order to access the event remotely, a live audio webcast will be
streamed from the R&D session. To access the webcast please visit the
Company's website www.medivir.se.

In a separate press release issued today Medivir announced positive phase
2b TMC435 data from the ASPIRE (C206) study. These results will be discussed
during the R&D session via a conference call at 15:00 (GMT)/ 16:00
(CET)/10:00 (EST).

To participate in the conference call at 15:00 (GMT) which will discuss
the phase 2b TMC435 ASPIRE (C206) data announced today please dial: UK: +44-
(0)20-7906-8535, Sweden Access Number: +46(0)85-063-9549 or US Access
Number: +1-703-865-2821. A seven day replay of the conference call can be
accessed via: UK: +44(0)20-3364-5943, Sweden: +46(0)20-089-6353, US: +1-
866-286-6997, please quote the passcode 281259#.

About Medivir

Medivir is an emerging research-based specialty pharmaceutical company
focused on the development of high-value treatments for infectious diseases.
Medivir has world class expertise in polymerase and protease drug targets and
drug development. Medivir has a strong R&D portfolio and has recently
launched its first product Xerese(TM)/Xerclear(R). Medivir's key pipeline
asset, TMC435, a protease inhibitor, is in phase 2b clinical development for
Hepatitis C and is partnered with Tibotec Pharmaceuticals.

Xerese(TM)/Xerclear(R) is an innovative treatment for cold sores, which
has been approved in both the US and Europe. It is partnered with GSK to be
sold OTC in Europe and Russia and with Meda in North America. Medivir has
retained the Rx rights for Xerclear(R) in Sweden and Finland.

For more information about Medivir, please visit the Company's website:
www.medivir.se.

    For more information about Medivir, please contact:

    Medivir (www.medivir.se)
    Rein Piir, CFO & VP Investor Relations
    Mobile: +46-708-537-292

    M:Communications
    Europe: Mary-Jane Elliott / Emma Thompson / Amber Bielecka

    Medivir@mcomgroup.com
    +44(0)20-7920-2330

    USA: Jason Marshall
    +1-212-897-5497

For more information about Medivir, please contact: Medivir (www.medivir.se), Rein Piir, CFO & VP Investor Relations, Mobile: +46-708-537-292; M:Communications, Europe: Mary-Jane Elliott / Emma Thompson / Amber Bielecka; Medivir at mcomgroup.com, +44(0)20-7920-2330; USA: Jason Marshall, +1-212-897-5497